Merck outflanks Pfizer's 20-valent shot with pneumococcal vaccine approval for kids

Back in April, the FDA asked for more analysis from Merck on its 15-valent pneumococcal vaccine for children and pushed back its approval deadline by three months. As the three-month mark approaches, the FDA appears to be satisfied.

Merck announced today that the FDA approved its vaccine for children ages 6 weeks and up, making it the third pneumococcal shot approved for children. The vaccine, which is marketed as Vaxneuvance, was already OK’d for adults back in July 2021.